File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Circulating EM66 is a highly sensitive marker for the diagnosis and follow-up of pheochromocytoma

TitleCirculating EM66 is a highly sensitive marker for the diagnosis and follow-up of pheochromocytoma
Authors
KeywordsChromogranins
EM66
Neuroendocrine tumor
Pheochromocytoma
Plasma marker
Secretogranin II
Issue Date2006
PublisherJohn Wiley & Sons, Inc.. The Journal's web site is located at http://www3.interscience.wiley.com/journal/29331/home
Citation
International Journal Of Cancer, 2006, v. 118 n. 8, p. 2003-2012 How to Cite?
AbstractWe have previously demonstrated that measurement of tissue concentration of the novel secretogranin II-derived peptide EM66 may help to discriminate between benign and malignant pheochromocytomas. The aim of the present study was to characterize EM66 in plasma and urine of healthy volunteers and pheochromocytoma patients, in order to further evaluate the usefulness of this peptide as a circulating marker for the management of the tumors. HPLC analysis of plasma and urine samples demonstrated that the EM66-immunoreactive material coeluted with the recombinant peptide. In healthy volunteers, plasma and urinary EM66 levels were, respectively, 2.6 (1.9-3.7) ng/ml and 2.9 (1.9-4.6) ng/ml. In patients with pheochromocytoma, plasma EM66 levels were 10-fold higher than those of healthy volunteers (26.9 (7.3-44) ng/ml), and returned to normal values after removal of the tumor. In contrast, urinary EM66 levels were not significantly different from those of healthy volunteers (3.2 (2.2-3.9) ng/ml). Measurement of total or free plasma metanephrines and 24 hr urinary metanephrines in our series of patients revealed that these tests, taken separately, are less sensitive than the EM66 determination. Pheochromocytes in primary culture secreted high levels of EM66, suggesting that the chromaffin tumor was actually responsible for the increased plasma peptide concentrations in the patients. These data indicate that EM66 is secreted in the general circulation and that elevated plasma EM66 levels are correlated with the occurrence of pheochromocytoma. Thus, EM66 is a sensitive plasma marker that should be considered as a complementary tool in the management of pheochromocytoma. © 2005 Wiley-Liss, Inc.
Persistent Identifierhttp://hdl.handle.net/10722/84750
ISSN
2015 Impact Factor: 5.531
2015 SCImago Journal Rankings: 2.657
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorGuillemot, Jen_HK
dc.contributor.authorAnouar, Yen_HK
dc.contributor.authorMonteroHadjadje, Men_HK
dc.contributor.authorGrouzmann, Een_HK
dc.contributor.authorGrumolato, Len_HK
dc.contributor.authorRoshmaninhoSalgado, Jen_HK
dc.contributor.authorTurquier, Ven_HK
dc.contributor.authorDuparc, Cen_HK
dc.contributor.authorLefebvre, Hen_HK
dc.contributor.authorPlouin, PFen_HK
dc.contributor.authorKlein, Men_HK
dc.contributor.authorMuresan, Men_HK
dc.contributor.authorChow, BKCen_HK
dc.contributor.authorVaudry, Hen_HK
dc.contributor.authorYon, Len_HK
dc.date.accessioned2010-09-06T08:56:41Z-
dc.date.available2010-09-06T08:56:41Z-
dc.date.issued2006en_HK
dc.identifier.citationInternational Journal Of Cancer, 2006, v. 118 n. 8, p. 2003-2012en_HK
dc.identifier.issn0020-7136en_HK
dc.identifier.urihttp://hdl.handle.net/10722/84750-
dc.description.abstractWe have previously demonstrated that measurement of tissue concentration of the novel secretogranin II-derived peptide EM66 may help to discriminate between benign and malignant pheochromocytomas. The aim of the present study was to characterize EM66 in plasma and urine of healthy volunteers and pheochromocytoma patients, in order to further evaluate the usefulness of this peptide as a circulating marker for the management of the tumors. HPLC analysis of plasma and urine samples demonstrated that the EM66-immunoreactive material coeluted with the recombinant peptide. In healthy volunteers, plasma and urinary EM66 levels were, respectively, 2.6 (1.9-3.7) ng/ml and 2.9 (1.9-4.6) ng/ml. In patients with pheochromocytoma, plasma EM66 levels were 10-fold higher than those of healthy volunteers (26.9 (7.3-44) ng/ml), and returned to normal values after removal of the tumor. In contrast, urinary EM66 levels were not significantly different from those of healthy volunteers (3.2 (2.2-3.9) ng/ml). Measurement of total or free plasma metanephrines and 24 hr urinary metanephrines in our series of patients revealed that these tests, taken separately, are less sensitive than the EM66 determination. Pheochromocytes in primary culture secreted high levels of EM66, suggesting that the chromaffin tumor was actually responsible for the increased plasma peptide concentrations in the patients. These data indicate that EM66 is secreted in the general circulation and that elevated plasma EM66 levels are correlated with the occurrence of pheochromocytoma. Thus, EM66 is a sensitive plasma marker that should be considered as a complementary tool in the management of pheochromocytoma. © 2005 Wiley-Liss, Inc.en_HK
dc.languageengen_HK
dc.publisherJohn Wiley & Sons, Inc.. The Journal's web site is located at http://www3.interscience.wiley.com/journal/29331/homeen_HK
dc.relation.ispartofInternational Journal of Canceren_HK
dc.rightsInternational Journal of Cancer. Copyright © John Wiley & Sons, Inc.en_HK
dc.subjectChromograninsen_HK
dc.subjectEM66en_HK
dc.subjectNeuroendocrine tumoren_HK
dc.subjectPheochromocytomaen_HK
dc.subjectPlasma markeren_HK
dc.subjectSecretogranin IIen_HK
dc.titleCirculating EM66 is a highly sensitive marker for the diagnosis and follow-up of pheochromocytomaen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0020-7136&volume=118&spage=2003&epage=2012&date=2006&atitle=Circulating+EM66+is+a+highly+sensitive+marker+for+the+diagnosis+and+follow-up+of+pheochromocytomaen_HK
dc.identifier.emailChow, BKC: bkcc@hku.hken_HK
dc.identifier.authorityChow, BKC=rp00681en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1002/ijc.21571en_HK
dc.identifier.pmid16287097-
dc.identifier.scopuseid_2-s2.0-33645213708en_HK
dc.identifier.hkuros115518en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-33645213708&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume118en_HK
dc.identifier.issue8en_HK
dc.identifier.spage2003en_HK
dc.identifier.epage2012en_HK
dc.identifier.isiWOS:000236397200022-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridGuillemot, J=7005329096en_HK
dc.identifier.scopusauthoridAnouar, Y=7003561768en_HK
dc.identifier.scopusauthoridMonteroHadjadje, M=6506736251en_HK
dc.identifier.scopusauthoridGrouzmann, E=7003750999en_HK
dc.identifier.scopusauthoridGrumolato, L=6505829981en_HK
dc.identifier.scopusauthoridRoshmaninhoSalgado, J=12792141100en_HK
dc.identifier.scopusauthoridTurquier, V=6603468015en_HK
dc.identifier.scopusauthoridDuparc, C=6507666133en_HK
dc.identifier.scopusauthoridLefebvre, H=7006290022en_HK
dc.identifier.scopusauthoridPlouin, PF=24290822400en_HK
dc.identifier.scopusauthoridKlein, M=7404420188en_HK
dc.identifier.scopusauthoridMuresan, M=8982350500en_HK
dc.identifier.scopusauthoridChow, BKC=7102826193en_HK
dc.identifier.scopusauthoridVaudry, H=35446602600en_HK
dc.identifier.scopusauthoridYon, L=6603856999en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats